Loading
A phase 2 trial of Evorpacept, Trastuzumab, Capecitabine, Eribulin, Gemcitabine and Vinorelbine in HER2-positive breast cancer, run by ALX Oncology Inc., now recruiting.
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer is a phase 2 interventional study registered as NCT07007559 by ALX Oncology Inc., with 120 participants planned, started 2025-12-10 and due to reach its primary completion in 2027-12. Interventions recorded: Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin and Gemcitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Trastuzumab, Capecitabine and the tag pipeline.
Shares Trastuzumab, Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/